InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,480.76
(
-0.11%
)
US TECH 100
19,287.20
(
-0.62%
)
Dow Jones
39,201.61
(
0.94%
)
Brent Oil
85.15
(
0.53%
)
Bitcoin
65,067.29
(
0.15%
)

Replies to post #194470 on Biotech Values

Replies to #194470 on Biotech Values

DewDiligence

08/19/15 9:12 AM

#194474 RE: WorstLuck #194470

As an ENTA shareholder, I’d like to see ABBV’s voucher used for the ABT-493/ABT-530 pan-genotypic HCV regimen.

DewDiligence

02/10/16 12:46 PM

#199629 RE: WorstLuck #194470

(ENTA)—ABBV still hasn’t used its FDA priority review voucher purchased for $350M in Aug 2015 (#msg-116321586). IMO, it’s becoming more and more likely ABBV will use it for the ABT-493/ABT-530 pan-genotypic HCV regimen, which has six phase-3 trials in progress (#msg-119900756).

DewDiligence

02/02/17 9:17 AM

#208666 RE: WorstLuck #194470

Q for anyone: What will ABBV use the PRV for?